THERAPY DOSSIER · th-71a10f950397

Compound 21 (C21) and diminazene aceturate (Dize), alone or in combination

Drug · Resolved on the lead agent Compound 21, now named buloxibutid (Vicore Pharma), a selective angiotensin AT2 receptor agonist; ChEMBL holds no mechanism record so no action_type is recorded here. Co-agent diminazene aceturate resolves separately to CHEMBL35241 (DIMINAZENE, max_phase 2, natural product flag true, no mechanism record) and is a reported ACE2 activator; its ClinicalTrials.gov keyword search returned only off-target ophthalmic surgery studies, so no diminazene trial is recorded.

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Resolved on the lead agent Compound 21, now named buloxibutid (Vicore Pharma), a selective angiotensin AT2 receptor agonist; ChEMBL holds no mechanism record so no action_type is recorded here. Co-agent diminazene aceturate resolves separately to CHEMBL35241 (DIMINAZENE, max_phase 2, natural product flag true, no mechanism record) and is a reported ACE2 activator; its ClinicalTrials.gov keyword search returned only off-target ophthalmic surgery studies, so no diminazene trial is recorded.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL189568 ↗
ChEMBL max phase: 0.5 / 4 (development scale, not regulatory approval)
Synonyms: C21; C-21; Compound 21; M-24; AT2 agonist compound 21; Buloxibutid
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06588686 ↗PHASE2active not recruiting

Randomised, Double-blind, Placebo-controlled, Multicentre Trial of 2 Doses of Buloxibutid Over 52 Weeks in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Enrolment: 378 · Results not recorded

NCT04533022 ↗PHASE2completed

Phase 2 Multicentre Open-label Single-arm Trial of Safety, Efficacy and Pharmacokinetics of C21 in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Enrolment: 52 · Results not recorded

NCT04878913 ↗Phase not recordedcompleted

Retrospective Multicentre Follow-up Study of the Effect of C21 on Lung Pathology in Subjects Previously Hospitalised With COVID-19 (VP-C21-006)

COVID-19 · COVID-19 Pneumonia

Enrolment: 35 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32979558 ↗2020Reported benefit

Ameliorative effect of AT2R and ACE2 activation on ischemic renal injury associated cardiac and hepatic dysfunction.

RatIschaemia-reperfusionRenalWistarMaleC21 intraperitoneal; Dize oralC21 0.3 mg/kg/day; Dize 5 mg/kg/day

Model: Bilateral ischaemic renal injury (bilateral renal ischaemia followed by 24 h reperfusion), in non-diabetic rats and in streptozotocin-induced diabetic rats (streptozotocin 55 mg/kg i.p.)

Ischaemic renal injury produced cardiac and hepatic injury with altered oxidant/antioxidant balance, raised inflammatory signalling and altered RAS component expression. Combined AT2R agonist and ACE2 activator therapy inhibited oxidative stress, downregulated inflammation and enhanced the cardio-h…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…

Compound 21 (C21) and diminazene aceturate (Dize), alone or in combination